Enoximone (MDL 17,043) for stable, chronic heart failure secondary to ischemic or idiopathic cardiomyopathy

Karl Weber, Joseph S. Janicki, Mukesh C. Jain

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

To examine the efficacy and safety of enoximone for treatment of patients with chronic, clinically stable cardiac failure secondary to ischemic or myopathic heart disease, 31 patients were enrolled into an early phase II trial. The hemodynamic response to intravenous and oral enoximone was assessed and compared with the response to dobutamine therapy (5 to 10 μg/kg/min). Maximal O2 uptake, an objective measure of effort tolerance, was serially monitored. Intravenous (1 to 2 mg/kg) and oral (1 to 2 mg/kg) enoximone improved (p < 0.05) cardiac index while reducing right atrial and wedge pressures to a greater extent than dobutamine. The salutary hemodynamic response to oral enoximone was sustained for 6 to 8 hours and was not associated with subacute drug tolerance. Maximal O2 uptake was increased (p < 0.05) at 2, 4, 8, 12, 24 and 52 weeks of oral enoximone therapy (1.4 ±0.5 mg/kg every 8 hours) while radionuclide ejection fraction at 65 weeks increased (p < 0.05) from baseline (39 ± 16% vs 30 ± 9%). Nine patients, 8 of whom were in functional class III or IV on enrollment, died after a mean of 18 weeks: 4 from cardiac failure and 5 suddenly. Two patients had adverse gastrointestinal effects. Oral enoximone (1 to 2 mg/kg every 8 hours) appears to be useful in the short- and long-term management of clinically stable, chronic cardiac failure. Controlled phase III trials are warranted.

Original languageEnglish (US)
Pages (from-to)589-595
Number of pages7
JournalThe American journal of cardiology
Volume58
Issue number7
DOIs
StatePublished - Sep 15 1986
Externally publishedYes

Fingerprint

Enoximone
Cardiomyopathies
Heart Failure
Dobutamine
Hemodynamics
Drug Tolerance
Pulmonary Wedge Pressure
Atrial Pressure
Radioisotopes
Heart Diseases
Therapeutics
Safety

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Enoximone (MDL 17,043) for stable, chronic heart failure secondary to ischemic or idiopathic cardiomyopathy. / Weber, Karl; Janicki, Joseph S.; Jain, Mukesh C.

In: The American journal of cardiology, Vol. 58, No. 7, 15.09.1986, p. 589-595.

Research output: Contribution to journalArticle

@article{3445ac19d8ff4339aa0d74d4d6ee01e4,
title = "Enoximone (MDL 17,043) for stable, chronic heart failure secondary to ischemic or idiopathic cardiomyopathy",
abstract = "To examine the efficacy and safety of enoximone for treatment of patients with chronic, clinically stable cardiac failure secondary to ischemic or myopathic heart disease, 31 patients were enrolled into an early phase II trial. The hemodynamic response to intravenous and oral enoximone was assessed and compared with the response to dobutamine therapy (5 to 10 μg/kg/min). Maximal O2 uptake, an objective measure of effort tolerance, was serially monitored. Intravenous (1 to 2 mg/kg) and oral (1 to 2 mg/kg) enoximone improved (p < 0.05) cardiac index while reducing right atrial and wedge pressures to a greater extent than dobutamine. The salutary hemodynamic response to oral enoximone was sustained for 6 to 8 hours and was not associated with subacute drug tolerance. Maximal O2 uptake was increased (p < 0.05) at 2, 4, 8, 12, 24 and 52 weeks of oral enoximone therapy (1.4 ±0.5 mg/kg every 8 hours) while radionuclide ejection fraction at 65 weeks increased (p < 0.05) from baseline (39 ± 16{\%} vs 30 ± 9{\%}). Nine patients, 8 of whom were in functional class III or IV on enrollment, died after a mean of 18 weeks: 4 from cardiac failure and 5 suddenly. Two patients had adverse gastrointestinal effects. Oral enoximone (1 to 2 mg/kg every 8 hours) appears to be useful in the short- and long-term management of clinically stable, chronic cardiac failure. Controlled phase III trials are warranted.",
author = "Karl Weber and Janicki, {Joseph S.} and Jain, {Mukesh C.}",
year = "1986",
month = "9",
day = "15",
doi = "10.1016/0002-9149(86)90281-X",
language = "English (US)",
volume = "58",
pages = "589--595",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Enoximone (MDL 17,043) for stable, chronic heart failure secondary to ischemic or idiopathic cardiomyopathy

AU - Weber, Karl

AU - Janicki, Joseph S.

AU - Jain, Mukesh C.

PY - 1986/9/15

Y1 - 1986/9/15

N2 - To examine the efficacy and safety of enoximone for treatment of patients with chronic, clinically stable cardiac failure secondary to ischemic or myopathic heart disease, 31 patients were enrolled into an early phase II trial. The hemodynamic response to intravenous and oral enoximone was assessed and compared with the response to dobutamine therapy (5 to 10 μg/kg/min). Maximal O2 uptake, an objective measure of effort tolerance, was serially monitored. Intravenous (1 to 2 mg/kg) and oral (1 to 2 mg/kg) enoximone improved (p < 0.05) cardiac index while reducing right atrial and wedge pressures to a greater extent than dobutamine. The salutary hemodynamic response to oral enoximone was sustained for 6 to 8 hours and was not associated with subacute drug tolerance. Maximal O2 uptake was increased (p < 0.05) at 2, 4, 8, 12, 24 and 52 weeks of oral enoximone therapy (1.4 ±0.5 mg/kg every 8 hours) while radionuclide ejection fraction at 65 weeks increased (p < 0.05) from baseline (39 ± 16% vs 30 ± 9%). Nine patients, 8 of whom were in functional class III or IV on enrollment, died after a mean of 18 weeks: 4 from cardiac failure and 5 suddenly. Two patients had adverse gastrointestinal effects. Oral enoximone (1 to 2 mg/kg every 8 hours) appears to be useful in the short- and long-term management of clinically stable, chronic cardiac failure. Controlled phase III trials are warranted.

AB - To examine the efficacy and safety of enoximone for treatment of patients with chronic, clinically stable cardiac failure secondary to ischemic or myopathic heart disease, 31 patients were enrolled into an early phase II trial. The hemodynamic response to intravenous and oral enoximone was assessed and compared with the response to dobutamine therapy (5 to 10 μg/kg/min). Maximal O2 uptake, an objective measure of effort tolerance, was serially monitored. Intravenous (1 to 2 mg/kg) and oral (1 to 2 mg/kg) enoximone improved (p < 0.05) cardiac index while reducing right atrial and wedge pressures to a greater extent than dobutamine. The salutary hemodynamic response to oral enoximone was sustained for 6 to 8 hours and was not associated with subacute drug tolerance. Maximal O2 uptake was increased (p < 0.05) at 2, 4, 8, 12, 24 and 52 weeks of oral enoximone therapy (1.4 ±0.5 mg/kg every 8 hours) while radionuclide ejection fraction at 65 weeks increased (p < 0.05) from baseline (39 ± 16% vs 30 ± 9%). Nine patients, 8 of whom were in functional class III or IV on enrollment, died after a mean of 18 weeks: 4 from cardiac failure and 5 suddenly. Two patients had adverse gastrointestinal effects. Oral enoximone (1 to 2 mg/kg every 8 hours) appears to be useful in the short- and long-term management of clinically stable, chronic cardiac failure. Controlled phase III trials are warranted.

UR - http://www.scopus.com/inward/record.url?scp=0022540049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022540049&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(86)90281-X

DO - 10.1016/0002-9149(86)90281-X

M3 - Article

VL - 58

SP - 589

EP - 595

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 7

ER -